<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469273</url>
  </required_header>
  <id_info>
    <org_study_id>MU 0932 BL</org_study_id>
    <nct_id>NCT01469273</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Gastrointestinal Infections With EcN</brief_title>
  <acronym>PIURA</acronym>
  <official_title>Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Bartolome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo y Enfermedades Metabolicas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital San Bartolome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This interventional trial shall investigate the efficacy and tolerance of a suspension with&#xD;
      non-pathogenic probiotic E. coli strain Nissle (EcN) on prophylaxis against gastrointestinal&#xD;
      infections in newborn and infants. ECN-SUSPENSION is a probiotic containing viable E. coli&#xD;
      bacteria of the non-pathogenic Nissle 1917 strain at a concentration of 10exp8 cells per ml.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newborns (treatment-group E) and infants at the age of 6 months (treatment-group L) shall be&#xD;
      treated with 1 x 1 ml ECN-SUSPENSION for 10 days and observed until the age of 12&#xD;
      months.Treatment-group E (newborn) will receive EcN-Suspension on the first 10 days of life&#xD;
      and will be observed for the next 12 months. Treatment-group L (infants at the age of 6&#xD;
      months) will receive EcN-Suspension on the first 10 days of their seventh month of life and&#xD;
      will be observed for the next 6 months.The corresponding control group will remain untreated&#xD;
      and will be observed only for 12 months. According to the hospitals daily routine the&#xD;
      inclusion and exclusion criteria will be checked. All newborns meeting the inclusion criteria&#xD;
      will be included into the trial. Patients' anamnestic data and general health status are&#xD;
      recorded at the initial control.Controls are performed according to the time schedule&#xD;
      normally used in the hospital functioning as a trial site. According to this, during each&#xD;
      monthly control data on the efficacy and safety are recorded. The final control for assessing&#xD;
      the tolerance and efficacy of the trial medication is conducted along with a physical&#xD;
      examination after an observation period of 12 months.In this study, diarrhea is defined as&#xD;
      increase of stool frequency to &gt;3 watery or loose stools in 24 hours on at least two or more&#xD;
      consecutive days.The prophylaxis against gastrointestinal infections with EcN-Suspension is&#xD;
      expected to result in a decrease of the number episodes of diarrhea in comparison to the&#xD;
      untreated control. The primary efficacy criterion is the number of episodes of diarrhea&#xD;
      caused by gastrointestinal infection within the first 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of diarrhea episodes</measure>
    <time_frame>12 months / first year of life</time_frame>
    <description>To show superiority of a prophylaxis with a probiotic suspension containing E. coli strain Nissle against gastrointestinal infections associated with diarrhea, compared to an untreated control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days with diarrhea</measure>
    <time_frame>12 months / first year of life</time_frame>
    <description>To show prophylaxis with a probiotic suspension containing E. coli strain Nissle against gastrointestinal infections associated with diarrhea within the first 12 months of life compared to an untreated control group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Infantile Diarrhea</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only observation; observation period: 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Treatment group (E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Treatment Group (L)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mutaflor® Suspension</intervention_name>
    <description>Application of Mutaflor-Suspension on 10 consecutive days.</description>
    <arm_group_label>Early Treatment group (E)</arm_group_label>
    <arm_group_label>Late Treatment Group (L)</arm_group_label>
    <other_name>EcN</other_name>
    <other_name>Mutaflor</other_name>
    <other_name>Newborn</other_name>
    <other_name>Nissle</other_name>
    <other_name>Prophylaxis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent form signed by the patient's parents or legal guardians.&#xD;
&#xD;
          -  Term born infants.&#xD;
&#xD;
               -  Age &lt; 2 days&#xD;
&#xD;
               -  Gestational age from 38-42 weeks of gestation&#xD;
&#xD;
               -  Birth weight from 2500-3750 gr.&#xD;
&#xD;
               -  Normal delivery (eutocia)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Simultaneous participation in another clinical study&#xD;
&#xD;
          -  Consumption of food supplements or medicines containing live micro-organisms or their&#xD;
             metabolic products or components during the study&#xD;
&#xD;
          -  Other reasons which in the opinion of the investigator provide a reason against the&#xD;
             inclusion of the patient in the study.&#xD;
&#xD;
          -  Autoimmune disease·Severe sepsis or severe systemic injury&#xD;
&#xD;
          -  Immunosuppressive treatment&#xD;
&#xD;
          -  Severe co-morbidities diseases of the:&#xD;
&#xD;
               -  Heart&#xD;
&#xD;
               -  Liver&#xD;
&#xD;
               -  Kidney&#xD;
&#xD;
          -  Genetic disease&#xD;
&#xD;
          -  Other serious associated diseases, which in the opinion of the investigator, cast a&#xD;
             doubt on the implementation of the test according to the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Bindels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Bartolome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delfina Cetraro, MD</last_name>
    <phone>+51 1 4245217</phone>
    <email>finacetrarocardo@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleana Calderon, CRA</last_name>
    <phone>+51 1 986674496</phone>
    <email>eleana_calderon@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud Los Algarrobos</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Segundo Montoya, MD</last_name>
      <phone>+51 7335 1635</phone>
    </contact>
    <investigator>
      <last_name>Segundo Montoya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Materno Inftantil de Castilla (CESAMICA)</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Luna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Luna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Materno Infantil Santa Rosa</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Luna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Luna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diarrhea</keyword>
  <keyword>EcN</keyword>
  <keyword>E. coli strain Nissle 1917</keyword>
  <keyword>Gastrointestinal infection</keyword>
  <keyword>Infant</keyword>
  <keyword>Newborn</keyword>
  <keyword>Probiotic drug</keyword>
  <keyword>Prevention</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Diarrhea, Infantile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

